Medical/Pharmaceuticals

Hanmi Science Consortium Drives Ambitious Project for Worldwide Vaccine Equity

SEOUL, South Korea, Oct. 29, 2021 /PRNewswire/ -- Hanmi Science doesn't just want the world to know they are committed to vaccine equity, they want to prove it. Mr. Lim, CEO of Hanmi Science, echoes the concerns of Mr.Bill Gates, co-founder of the Bill & Melinda Gates Foundation. As Mr. Gates sta...

2021-10-29 09:27 3333

Exosystems Raises $3.9M Series A Funding, on Mission to Provide AI-based Digital Care for Musculoskeletal System

SEOUL, South Korea, Oct. 28, 2021 /PRNewswire/ -- Exosystems, an artificial intelligence (AI)-based digital healthcare company and a member ofBorn2Global Centre, has succeeded in attracting Series A funding worth USD 3.9 million from SBI Investment, Laguna Investment, and Korea Technology Finance...

2021-10-29 07:47 2292

World Stroke Day: Global survey reveals only 35% hospitals worldwide provide essential stroke treatment

GENEVA, Oct. 29, 2021 /PRNewswire/ -- On World Stroke Day, 29 October, the World Stroke Organization (WSO) is calling for urgent action after a survey by the WSO and the World Health Organization (WHO) found that only 35% of hospitals worldwide provide essential clot-busting medicine tissue plasm...

2021-10-29 06:01 2089

ImmunoForge Inc. receives U.S. FDA ODD for PF1801

SEOUL, South Korea and SILVER SPRING, Md., Oct. 29, 2021 /PRNewswire/ -- ImmunoForge (Co-CEOsSung-Min Ahn, Kiho Chang), a company specializing in developing new drugs for rare musculoskeletal diseases, has reported that their new drug candidate PF1801 which is in development for treatment of D...

2021-10-29 05:50 4532

EZZ Marks Transition to Genomic Health Following Exceptional FY21 Performance

About EZZ Life Science Holdings EZZ Life Science Holding Limited (ASX:EZZ) is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papi...

2021-10-29 04:05 4637

FII Institute Announces Investment in AZmed, Helping to Address Global Shortage in Radiologists

RIYADH, Saudi Arabia, Oct. 28, 2021 /PRNewswire/ -- The Future Investment Initiative (FII) Institute has announced a1 million EUR investment in AZmed, developers of Artificial Intelligence-enabled diagnostic applications which can help address the shortage of radiologists around the world.

2021-10-28 23:15 4443

Aiming for Global CDMO, Xcell Therapeutics opens an export route to 62 countries with cell therapy culture technology.

SEOUL, South Korea, Oct. 28, 2021 /PRNewswire/ -- In a hair follicle, there are "dermal follicle papilla cells" that appear 3,000 grapes clustered together. The name was given because its outline resembles the papilla of the human body when observed under a microscope. Hair loss occurs when der...

2021-10-28 21:00 1888

Osfirm to Launch Novel Implantable Biomaterial Whitlockite with Excellent Biodegradability and Bone Regenerative and Reconstructive Properties into Global Market by the Year 2023

SEOUL, South Korea, Oct. 28, 2021 /PRNewswire/ -- In 1941, "whitlockite," the second most abundant inorganic mineral of the bone was named in honor of Herbert Whitlockite, Curator of Minerals and Gems in the American Museum of Natural History inNew York. Whitlockite is a unique form of magnesium ...

2021-10-28 21:00 1883

Merck Drives New Innovation & Adds Capacity to Advance Next Generation Antibody-drug Conjugate (ADC) Therapies

- Merck's unique technology, ChetoSensar™, gives new promise to ADCs by alleviating solubility challenges  - New DOLCORE™ platform increases speed-to-market by up to a year - Expanded ADC clinical manufacturing facility drives next generation ADCs, building on company's 15 years of ADC Contract...

2021-10-28 21:00 4419

HanAll Biopharma Reports Third Quarter 2021 Results

* Q3'21 sales of KRW 25.5 billion increased 15% from the same period last year * Q3'21 operating profit of KRW 2.2 billion grew by 120% compared to Q3'20 * Nine months sales of KRW 76.7 billion and operating profit of KRW 9.2 billion rose by 15% and 67% YoY, repectively SEOUL, South Korea, Oct...

2021-10-28 21:00 2742

BioVaxys Further Expands Intellectual Property Portfolio in Global Markets

- Files Applications for International Patent and Trademark Protection of CoviDTH VANCOUVER, BC, Oct. 28, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has broadened the patent coverage on CoviDTH, its T ...

2021-10-28 20:00 4038

Interim report for Q3 2021 : Bactiguard Holding AB (publ)

STOCKHOLM, Oct. 28, 2021 /PRNewswire/ -- Capital injection initiates a new phase of accelerated expansion Third quarter (July-September 2021) * Revenues amounted to SEK 45.2 (34.1) million, an increase of 32%. Adjusted for currency effects revenues increased by 36%. * EBITDA amounted to SEK ...

2021-10-28 15:23 2402

Mentice publishes the company's interim report for the period January-September 2021

STOCKHOLM, Oct. 28, 2021 /PRNewswire/ -- Third quarter (July–September 2021) and the first nine months of the year (January-September 2021) * Order intake amounted to 51.8 (34.6) MSEK for the third quarter and 131.9 (95.5) MSEK for the first nine months of the year. * Order book by the end ...

2021-10-28 15:07 2039

WuXi Biologics Completes GMP Inspection by Health Canada for Drug Substance Facility

- Successfully completed nearly 20 regulatory inspections in total, including 13 regulatory inspections since the start of 2021 WUXI, China, Oct. 27, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced th...

2021-10-28 08:30 2639

Innovent and NeoCura Announce Strategic Collaboration to Study the Combination Therapy of Sintilimab and Neoantigen Vaccine NEO_PLIN2101 for Cancer Treatment in China

SAN FRANCISCO and SUZHOU, China, Oct. 28, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-10-28 08:00 4153

Mallinckrodt and Terumo Blood and Cell Technologies Announce Positive Recommendations in Australia for Public Funding of UVADEX® (methoxsalen) for ECP Administration with the THERAKOS® CELLEX® Photopheresis System for Chronic Graft Versus Host Disease (cGvHD) in Adults

– In a dual-review process, two independent advisory committees to the Australian Minister for Health recommended reimbursement based on a favorable clinical and cost-effectiveness comparison – DUBLIN and LAKEWOOD, Colo., Oct. 28, 2021 /PRNewswire/ -- Mallinckrodt plc  (OTCMKTS: MNKKQ), a global ...

2021-10-28 05:48 2833

Ingersoll Rand and its Brands Support the Public Health in the Post-Pandemic Era

SINGAPORE, Oct. 27, 2021 /PRNewswire/ -- Ingersoll Rand Inc. (NYSE:IR), a global provider of mission-critical flow creation and industrial solutions, is providing compressed air and vacuum, material handling, and metering solutions to the medical and pharmaceutical industries. Its cutting-edge co...

2021-10-28 05:47 4265

New Wellbeing Trends Report 2030 Reveals Decade-long Impact of Pandemic Upheaval

SYDNEYOct. 28, 2021 /PRNewswire/ -- Jeunesse Global today shared the inaugural Wellness & Aesthetics Trends Report 2030, presenting key macro and micro trends that are set to influence the future of the wellbeing and beauty sectors, based on the evolution of audience behaviours and cultural shift...

2021-10-28 03:54 2749

Launch of Seegene's STARlet-AIOS: All-in-One System Fulfills Critical Need for Fully Automated, High-Throughput Real-Time PCR Testing

* A true walk away 'sample to answer' molecular diagnostic system designed for high throughput testing, offering a time-efficient and seamless workflow for clinical laboratories * Utilizes Seegene's patented, cutting-edge high multiplex real-time PCR technologies to provide 'Real' Ct values...

2021-10-27 23:40 2991

Frontier Biotechnologies' Long-acting Injectable (Aikening(R)), In A Two Drug Regimen, Proves Safe And Effective For Critically Ill Hospitalized AIDS Patients

LONDON, Oct. 27, 2021 /PRNewswire/ -- Frontier Biotechnologies today shared real-world evidence of Albuvirtide (ABT)-based two drug regimen's safety and efficacy for hospitalized AIDS patients at the European AIDS Clinical Society (EACS) Conference. Observations from a single-center, retrospec...

2021-10-27 22:08 2057
1 ... 640641642643644